Trial · NCT01698775
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 | Omarigliptin (Phase A) | -0.77 | 95% Confidence Interval -1.00 to -0.54 | Percent | |
| Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 | Placebo to Omarigliptin (Phase A) | -0.44 | 95% Confidence Interval -0.67 to -0.21 | Percent | |
| Percentage of Participants Who Experienced at Least One Adverse Event (Phase A: 24-week Placebo Controlled Period) | Omarigliptin (Phase A) | 66.0 | Percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Adverse Event (Phase A: 24-week Placebo Controlled Period) | Placebo to Omarigliptin (Phase A) | 69.8 | Percentage of participants | ||
| Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A: 24-week Placebo Controlled Period) | Omarigliptin (Phase A) | 2.8 | Percentage of participants | ||
| Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A: 24-week Placebo Controlled Period) | Placebo to Omarigliptin (Phase A) | 0.9 | Percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Adverse Event (Phase A: 24-week Placebo Controlled Period + Phase B: 30-week Active Controlled Period) | Omarigliptin (Phase A) → Omarigliptin (Phase B) | 77.4 | Percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Adverse Event (Phase A: 24-week Placebo Controlled Period + Phase B: 30-week Active Controlled Period) | Placebo to Omarigliptin (Phase A) → Glipizide (Phase B) | 78.3 | Percentage of participants | ||
| Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A: 24-week Placebo Controlled Period + Phase B: 30-week Active Controlled Period) | Omarigliptin (Phase A) → Omarigliptin (Phase B) | 6.6 | Percentage of participants | ||
| Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A: 24-week Placebo Controlled Period + Phase B: 30-week Active Controlled Period) | Placebo to Omarigliptin (Phase A) → Glipizide (Phase B) | 3.8 | Percentage of participants | ||
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 | Omarigliptin (Phase A) | -24.6 | 95% Confidence Interval -35.6 to -13.6 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 | Placebo to Omarigliptin (Phase A) | -20.7 | 95% Confidence Interval -31.8 to -9.5 | mg/dL | |
| Change From Baseline in A1C at Week 54 | Omarigliptin (Phase A) → Omarigliptin (Phase B) | -0.79 | 95% Confidence Interval -1.10 to -0.47 | Percent | |
| Change From Baseline in A1C at Week 54 | Placebo to Omarigliptin (Phase A) → Glipizide (Phase B) | -0.83 | 95% Confidence Interval -1.16 to -0.49 | Percent | |
| Change From Baseline in FPG at Week 54 | Omarigliptin (Phase A) → Omarigliptin (Phase B) | -19.3 | 95% Confidence Interval -36.5 to -2.1 | mg/dL | |
| Change From Baseline in FPG at Week 54 | Placebo to Omarigliptin (Phase A) → Glipizide (Phase B) | -16.4 | 95% Confidence Interval -34.4 to 1.6 | mg/dL | |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 24 | Omarigliptin (Phase A) | -0.5 | 95% Confidence Interval -2.1 to 1.2 | mL/min/1.73 m^2 | |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 24 | Placebo to Omarigliptin (Phase A) | -0.0 | 95% Confidence Interval -1.8 to 1.7 | mL/min/1.73 m^2 | |
| Change From Baseline in eGFR at Week 54 | Omarigliptin (Phase A) → Omarigliptin (Phase B) | -2.0 | 95% Confidence Interval -4.0 to -0.1 | mL/min/1.73 m^2 | |
| Change From Baseline in eGFR at Week 54 | Placebo to Omarigliptin (Phase A) → Glipizide (Phase B) | -2.3 | 95% Confidence Interval -4.3 to -0.2 | mL/min/1.73 m^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01698775/results